NASDAQ:ALNY Alnylam Pharmaceuticals Q3 2026 Earnings Report $231.53 -15.21 (-6.16%) As of 03:13 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Alnylam Pharmaceuticals EPS ResultsActual EPSN/AConsensus EPS $1.77Beat/MissN/AOne Year Ago EPSN/AAlnylam Pharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$1.43 billionBeat/MissN/AYoY Revenue GrowthN/AAlnylam Pharmaceuticals Announcement DetailsQuarterQ3 2026Date10/29/2026TimeBefore Market OpensConference Call DateThursday, October 29, 2026Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Alnylam Pharmaceuticals Earnings HeadlinesAMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CMSeptember 29 at 10:05 AM | marketscreener.comMAlnylam Pharmaceuticals: More Than Meets The Eye After CARDIO-TTRansformSeptember 28 at 12:11 PM | seekingalpha.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.October 1 at 1:00 AM | The Oxford Club (Ad)18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.September 28 at 5:23 AM | fool.comAlnylam Needs Stronger Amvuttra Execution To Justify More UpsideSeptember 26, 2026 | seekingalpha.comAquaBounty Technologies (NASDAQ:AQB) versus Alnylam Pharmaceuticals (NASDAQ:ALNY) Head-To-Head ComparisonSeptember 23, 2026 | americanbankingnews.comSee More Alnylam Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Alnylam Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alnylam Pharmaceuticals and other key companies, straight to your email. Email Address About Alnylam PharmaceuticalsAlnylam Pharmaceuticals (NASDAQ:ALNY) is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi), a biological process that can selectively reduce the production of disease-causing proteins. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Alnylam’s commercial products include ONPATTRO (patisiran), an RNAi therapy for hereditary transthyretin-mediated amyloidosis with polyneuropathy; GIVLAARI (givosiran), for acute hepatic porphyria; OXLUMO (lumasiran), for primary hyperoxaluria type 1; and AMVUTTRA (vutrisiran), for transthyretin-mediated amyloidosis. The company also develops investigational RNAi medicines for diseases affecting the liver, cardiovascular system, central nervous system, and other areas. The company serves patients and healthcare providers through commercial operations and partnerships in the United States and international markets. Alnylam has entered collaborations with pharmaceutical companies to support the development, manufacturing, and commercialization of certain products. Yvonne Greenstreet has served as Alnylam’s chief executive officer since 2022.View Alnylam Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Micron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCleared for Takeoff: AAR Corp. Expands Its Aerospace Aftermarket ReachJabil’s Double-Beat and Raise Is a Signal That This Rally Will ContinueMicrosoft's AI Spending Didn't Change—Wall Street's View of It DidL3Harris’ $6 Billion THAAD Win Comes at a Crucial Moment for the Stock Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
